Abstract | OBJECTIVE: METHODS: In this randomized, double-blind, placebo-controlled study, patients with T2DM and BMI of 30 to 50 kg/m2 received subcutaneous pegbelfermin (1, 5, or 20 mg daily or 20 mg weekly; n = 96) or placebo (n = 24) for 12 weeks. Primary end points were safety, tolerability, and change in HbA1c. Additional end points included insulin sensitivity, lipids, adiponectin, and disease progression biomarkers. RESULTS: CONCLUSIONS:
|
Authors | Edgar D Charles, Brent A Neuschwander-Tetri, Juan Pablo Frias, Sudeep Kundu, Yi Luo, Giridhar S Tirucherai, Rose Christian |
Journal | Obesity (Silver Spring, Md.)
(Obesity (Silver Spring))
Vol. 27
Issue 1
Pg. 41-49
(01 2019)
ISSN: 1930-739X [Electronic] United States |
PMID | 30520566
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS). |
Chemical References |
- Polyethylene Glycols
- Fibroblast Growth Factors
- Pegbelfermin
|
Topics |
- Adult
- Aged
- Diabetes Mellitus, Type 2
(drug therapy)
- Double-Blind Method
- Female
- Fibroblast Growth Factors
(analogs & derivatives, pharmacology, therapeutic use)
- Humans
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
(drug therapy, pathology)
- Obesity
(drug therapy)
- Polyethylene Glycols
(pharmacology, therapeutic use)
- Young Adult
|